G. Knoll, Trends in Kidney Transplantation over the Past Decade, Drugs, vol.22, issue.5, pp.3-10, 2008.
DOI : 10.2165/00003495-200868001-00002

A. Allison and E. Eugui, Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF), Clin Transplant, vol.10, issue.1 2, pp.77-84, 1996.

R. Bullingham, A. Nicholls, and B. Kamm, Clinical Pharmacokinetics of Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.34, issue.6, pp.429-55, 1998.
DOI : 10.2165/00003088-199834060-00002

B. Winter and T. Van-gelder, Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases, Nephrology Dialysis Transplantation, vol.23, issue.11, pp.3386-3394, 2008.
DOI : 10.1093/ndt/gfn497

L. Meur, Y. Buchler, M. Thierry, and A. , Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-503, 2007.
DOI : 10.1097/00007691-200412000-00005

T. Van-gelder, H. Silva, and J. De-fijter, Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial, Transplantation, vol.86, issue.8, pp.1043-51, 2008.
DOI : 10.1097/TP.0b013e318186f98a

L. Shaw, D. Holt, and M. Oellerich, Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion, Therapeutic Drug Monitoring, vol.23, issue.4, pp.305-320, 2001.
DOI : 10.1097/00007691-200108000-00001

A. Premaud, L. Meur, Y. Debord, and J. , Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods, Therapeutic Drug Monitoring, vol.27, issue.3, pp.354-61, 2005.
DOI : 10.1097/01.ftd.0000162231.90811.38

L. Guellec, C. Bourgoin, H. Buchler, and M. , Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients, Clinical Pharmacokinetics, vol.20, issue.6, pp.253-66, 2004.
DOI : 10.2165/00003088-200443040-00004

E. Trulock, J. Christie, and L. Edwards, Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart???Lung Transplantation Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.782-95, 2007.
DOI : 10.1016/j.healun.2007.06.003

C. Knoop, A. Haverich, and S. Fischer, Immunosuppressive therapy after human lung transplantation, European Respiratory Journal, vol.23, issue.1, pp.159-71, 2004.
DOI : 10.1183/09031936.03.00039203

G. Snell and G. Westall, Immunosuppression for Lung Transplantation, Drugs, vol.22, issue.11, pp.1531-1540, 2007.
DOI : 10.2165/00003495-200767110-00002

P. Jaksch, A. Kocher, and P. Neuhauser, Monitoring C2 Level Predicts Exposure in Maintenance Lung Transplant Patients Receiving the Microemulsion Formulation of Cyclosporine (Neoral), The Journal of Heart and Lung Transplantation, vol.24, issue.8, pp.1076-80, 2005.
DOI : 10.1016/j.healun.2003.05.002

M. Gerbase, M. Fathi, and A. Spiliopoulos, Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis, The Journal of Heart and Lung Transplantation, vol.22, issue.5, pp.587-90, 2003.
DOI : 10.1016/S1053-2498(02)01159-2

B. Winter, T. Van-gelder, and F. Sombogaard, Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients, Journal of Pharmacokinetics and Pharmacodynamics, vol.84, issue.3, pp.541-64, 2009.
DOI : 10.1007/s10928-009-9136-6

C. Monchaud and P. Marquet, Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II, Clinical Pharmacokinetics, vol.59, issue.3, pp.489-516, 2009.
DOI : 10.2165/11317240-000000000-00000

L. Ting, N. Partovi, and R. Levy, Limited Sampling Strategy for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients, Pharmacotherapy, vol.19, issue.9, pp.1232-1272, 2006.
DOI : 10.2165/00003088-200241050-00001

B. Winter, R. Mathot, and R. Van-hest, Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?, Expert Opinion on Drug Metabolism & Toxicology, vol.82, issue.2, pp.251-61, 2007.
DOI : 10.1097/01.ftd.0000179848.65266.aa

L. Guellec, C. Buchler, M. Giraudeau, and B. , Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy, European Journal of Clinical Pharmacology, vol.57, issue.11, pp.805-816, 2002.
DOI : 10.1007/s00228-001-0389-2

A. Premaud, J. Debord, and A. Rousseau, A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-884, 2005.
DOI : 10.2165/00003088-200544080-00005

M. Buchler, S. Caillard, and S. Barbier, , Mycophenolate Mofetil and a 6-Month Course of Steroids, American Journal of Transplantation, vol.6, issue.2, pp.2522-2553, 2007.
DOI : 10.1128/JVI.75.13.6022-6032.2001

K. Benkali, A. Premaud, and N. Picard, Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients, Clinical Pharmacokinetics, vol.76, issue.8, pp.805-821, 2009.
DOI : 10.2165/11318080-000000000-00000
URL : https://hal.archives-ouvertes.fr/hal-01390737

N. Djebli, N. Picard, and J. Rerolle, Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients, Pharmacogenetics and Genomics, vol.17, issue.5, pp.321-351, 2007.
DOI : 10.1097/FPC.0b013e32801430f8

N. Djebli, A. Rousseau, and G. Hoizey, Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients, Clinical Pharmacokinetics, vol.44, issue.11, pp.1135-1183, 2006.
DOI : 10.2165/00003088-200645110-00007

C. Monchaud, C. Pison, and M. Reynaud-gaubert, 202 New Tools for Mycophenolate Mofetil (MMF) Dose Optimization in Lung Transplant Recipients during the First Year Post-Transplantation: The STIMMUGREP Trial, The Journal of Heart and Lung Transplantation, vol.30, issue.4, p.74, 2011.
DOI : 10.1016/j.healun.2011.01.209

A. Premaud, A. Rousseau, and N. Picard, Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography???Tandem Mass Spectrometry, Therapeutic Drug Monitoring, vol.28, issue.2, pp.274-281, 2006.
DOI : 10.1097/01.ftd.0000197092.84935.ef

U. Wahlby, E. Jonsson, and M. Karlsson, Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis, AAPS PharmSci, vol.4, issue.4, p.27, 2002.
DOI : 10.1208/ps040427

E. Ette, P. Williams, and Y. Kim, Model Appropriateness and Population Pharmacokinetic Modeling, The Journal of Clinical Pharmacology, vol.43, issue.6, pp.610-633, 2003.
DOI : 10.1177/0091270003253624

P. Jadhav and J. Gobburu, A new equivalence based metric for predictive check to qualify mixed-effects models, The AAPS Journal, vol.7, issue.3, pp.523-554, 2005.
DOI : 10.1208/aapsj070353

A. Rousseau, F. Leger, L. Meur, and Y. , Population Pharmacokinetic Modeling of Oral Cyclosporin Using NONMEM, Therapeutic Drug Monitoring, vol.26, issue.1, pp.23-30, 2004.
DOI : 10.1097/00007691-200402000-00006

B. Frame, R. Miller, and R. Lalonde, Evaluation of Mixture Modeling with Count Data Using NONMEM, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.3, pp.167-83, 2003.
DOI : 10.1023/A:1025564409649

B. Winter, T. Van-gelder, and P. Glander, Population Pharmacokinetics of Mycophenolic Acid, Clinical Pharmacokinetics, vol.27, issue.3, pp.827-865, 2008.
DOI : 10.2165/0003088-200847120-00007

P. Lee, Design and power of a population pharmacokinetic study, Pharmaceutical Research, vol.18, issue.1, pp.75-82, 2001.
DOI : 10.1023/A:1011030827847

F. Musuamba, A. Rousseau, and J. Bosmans, Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus, Clinical Pharmacokinetics, vol.7, issue.11, pp.745-58, 2009.
DOI : 10.2165/11318060-000000000-00000

B. Shum, S. Duffull, and P. Taylor, Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil, British Journal of Clinical Pharmacology, vol.22, issue.2, pp.188-97, 2003.
DOI : 10.1046/j.1365-2125.2003.01863.x

R. Van-hest, T. Van-gelder, and A. Vulto, Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients, Clinical Pharmacokinetics, vol.43, issue.6, pp.1083-96, 2005.
DOI : 10.2165/00003088-200544100-00006

R. Van-hest, R. Mathot, and M. Pescovitz, Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients, Journal of the American Society of Nephrology, vol.17, issue.3, pp.871-80, 2006.
DOI : 10.1681/ASN.2005101070

B. Winter, R. Mathot, and F. Sombogaard, Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure: Implications for Therapeutic Drug Monitoring, Clinical Journal of the American Society of Nephrology, vol.6, issue.3, pp.656-63, 2011.
DOI : 10.2215/CJN.05440610

C. Sherwin, T. Fukuda, and H. Brunner, The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease, Clinical Pharmacokinetics, vol.11, issue.3-4, pp.1-24, 2011.
DOI : 10.2165/11536640-000000000-00000

U. Wahlby, E. Jonsson, and M. Karlsson, Assessment of actual significance levels for covariate effects in NONMEM, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.3, pp.231-52, 2001.
DOI : 10.1023/A:1011527125570

D. Hesselink, R. Van-hest, and R. Mathot, Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2, American Journal of Transplantation, vol.41, issue.1, pp.987-94, 2005.
DOI : 10.1046/j.1523-1755.2001.00782.x

N. Picard, S. Yee, and J. Woillard, The Role of Organic Anion???Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.87, issue.1, pp.100-108, 2010.
DOI : 10.1086/379378
URL : https://hal.archives-ouvertes.fr/inserm-00415314

F. Saint-marcoux, C. Knoop, and J. Debord, Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1345, 2005.
DOI : 10.2165/00003088-200544120-00010

L. Ting, N. Partovi, and R. Levy, Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients, Therapeutic Drug Monitoring, vol.30, issue.3, pp.282-91, 2008.
DOI : 10.1097/FTD.0b013e318166eba0

B. Winter, I. Neumann, and R. Van-hest, Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease, Therapeutic Drug Monitoring, vol.31, issue.3, pp.382-90, 2009.
DOI : 10.1097/FTD.0b013e3181a23f1a